EMA filing in hand and BLA submission imminent, tanruprubart's GBS bet hinges on FDA accepting placebo-controlled FORWARD data as registrational

Bull

FDA accepts the BLA for filing and grants Priority Review, validating the FORWARD placebo-controlled data as sufficient for registration — an outcome supported by the recently reported initial 10-patient cohort showing rapid, clinically meaningful functional gains within days of treatment. A standard or accelerated approval would position tanruprubart as the first targeted fast-acting GBS therapy, unlocking significant commercial opportunity in a condition where IVIG and plasma exchange remain the only standard of care. Approval would also trigger milestone tranches under the Oxford Finance credit facility, extending the financial runway.

Bear

The most significant failure mode is FDA refusing to file or issuing a Complete Response Letter on the grounds that the FORWARD dataset — with its initial 10-patient U.S./European cohort — is insufficient in size or statistical power to support a registrational conclusion without an additional adequate and well-controlled study. A second risk is that FDA disagrees with the chosen primary endpoint or the comparator design, given the logistical complexity of placebo-controlled trials in severe acute GBS where standard-of-care IVIG is widely available; any such deficiency letter would require a new or expanded trial, substantially delaying the program.